IDH1 and glioblastoma: Median overall survival was 21.5 months (95% CI 15.3-27.7) for patients with H3 G34-mutant diffuse hemispheric gliomas compared to 11.3 months (95% CI 9.7-13.0; P < .001) for IDH-wildtype glioblastoma patients in the reference cohort 1; yet, survival was poor in pediatric patients with H3 G34-mutant diffuse hemispheric glioma (Figure 4C).